Migraine and different digestive disorders, according to several clinical studies, are symptoms caused by this enzymatic deficiency in the bowel, which affects 20% of the population
Europapress 27th March, 2014 – Experts in neurology and gastroenterology have presented the results of three clinical studies, in Infarma Madrid 2014, which suggest that Diamine Oxidase deficiency should be considered a syndrome presenting digestive manifestations (such as constipation, abdominal pain or diarrhoea) and neurological manifestations (as migraine), all of them difficult to treat up to now.
The results of the mentioned research projects have been presented in the conference “Are we facing a new syndrome? Digestive and neurological manifestations of DAO deficiency”, conducted by Dr Ramon Tormo, specialist in Gastroenterology and Head of the Gastroenterology and Nutrition Unit of the Quirón Hospital in Barcelona; and Dr Joan Izquierdo, neurologist and Head of the Headache Unit of the General Hospital of Catalonia; both of them members of the International Society of DAO Deficiency.
Dr Ramón Tormo explains that we can be facing a new syndrome since the deficiency of DAO enzyme, which affects 20% of the population, can cause not only migraine but other symptoms, for example, gastrointestinal problems, vomiting, flatulence, abdominal pain or rhinitis. “All these disorders were considered separately but now they can be embedded within DAO deficiency”.
Several clinical studies have shown that deficiency of DAO enzyme is the trigger factor of migraine and other digestive disorders due to its participation in histamine metabolism.
DAO enzyme is a protein that degrades histamine, a molecule present in every food of our daily diet. People with low activity of this enzyme do not metabolize histamine properly and this molecule builds up and passes to the bloodstream causing several symptoms, such as migraine, which affects approximately 12% of the population and is ranked as number 19 in the list of the most disabling diseases, according to WHO data.
The clinical study led by Dr Ramón Tormo on the digestive origin of migraine concludes that “patients with chronic migraine and gastrointestinal symptoms tend to have a low activity of DAO enzyme”. All patients involved in this research were treated with a low histamine diet and received DAO enzyme supplement. Those patients suffering from migraine and vomiting experienced 80% reduction of the mentioned signs of pain. The results suggest to the different specialists that we can be facing a new syndrome, the deficiency of DAO (Diamine Oxidase) enzyme.
This clinical study will be presented next June in Jerusalem in the Congress of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), a prestigious professional organization which main objective is to promote children health, especially in the matter of nutritional and gastrointestinal status. The organization offers a high quality education for paediatric gastroenterology, hepatology and nutrition professionals in Europe.
Furthermore, the research project conducted by Dr Joan Izquierdo, presented in 2013 in the World Congress of Neurology in Vienna, shows that the 87% of patients with migraine also suffer from DAO deficiency, and the 90% of cases can be addressed through a prevention treatment with a dietary food based on DAO enzyme, without side effects and withdrawing the intake of any other drugs.